LTFS
GYRE icon

Ladenburg Thalmann Financial Services’s Gyre Therapeutics GYRE Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1
Closed – – 4717
2015
Q3 		$0 Hold
1
– – ﹤0.01% 4654
2015
Q2 		$1K Hold
1
– – ﹤0.01% 4489
2015
Q1 		$1K Hold
1
– – ﹤0.01% 4420
2014
Q4 		$1K Buy
+1
New +$1.93K ﹤0.01% 4202

Other funds holding GYRE

EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CCM
Colorado Capital Management Boulder, Colorado $293M AUM 22.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Ladenburg Thalmann Financial Services's GYRE Position: Q4 2015 in Review

Ladenburg Thalmann Financial Services sold out of Gyre Therapeutics (GYRE) in Q4 2015, closing a stake of 1 share.

Ladenburg Thalmann Financial Services first reported a position in GYRE in Q4 2014 and held it in 4 quarters. The position peaked at $1K in Q2 2015. 35 funds tracked by Wall St. Rank hold GYRE as of Q4 2015.

  • Ladenburg Thalmann Financial Services reported no remaining Gyre Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Ladenburg Thalmann Financial Services sold 1 Gyre Therapeutics share in Q4 2015.
  • Ladenburg Thalmann Financial Services first reported a position in Gyre Therapeutics in Q4 2014 and held it in 4 quarters.
  • Ladenburg Thalmann Financial Services's Gyre Therapeutics position peaked at $1K in Q2 2015.
  • 35 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2015.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2015, filed 16 Feb 2016.